Robin Shane Readnour

This profile gathers the share dealings of Robin Shane Readnour in AN2 Therapeutics, Inc., where the filings describe the role as board member. Over a trading history stretching from 29 March 2022 to 9 September 2026, the count stands at 33 filings.

The open-market side counts 16 purchases for €2.5M alongside 12 sales for €375k. The net balance comes to €2.1M on the buying side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant. So far in 2026, the count stands at no purchases and 8 sales.

In size, the median ticket on the buying side is €26k. 16 out of 16 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 11 September 2026 with an open-market sale (€2,709) in AN2 Therapeutics, Inc. The last insider purchase was made public on 10 December 2024, 683 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.